MESA LABORATORIES INC /CO/
Close on Oct 19, 2026
- Market cap
- $709.87M
- P/E (TTM)
- 145.1
- Dividend yield
- 0.52%
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $60.14M | – | – |
| Q4 FY2026 Ended Mar 31, 2026 | May 27, 2026 | Before market open | $63.72M | $-0.75 | $2.76 |
| Q3 FY2026 Ended Dec 31, 2025 | Feb 3, 2026 | Before market open | $65.13M | $0.65 | $3.07 |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $60.74M | $0.45 | $2.60 |
| Q1 FY2026 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $59.54M | $0.85 | $2.32 |
| Q4 FY2025 Ended Mar 31, 2025 | May 28, 2025 | Before market open | $62.14M | – | $2.23 |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 4, 2025 | Before market open | $62.84M | $-0.31 | $2.67 |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $57.83M | $0.63 | $2.62 |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 5, 2024 | Before market open | $58.17M | $0.62 | $2.58 |
| Q4 FY2024 Ended Mar 31, 2024 | Jun 5, 2024 | Before market open | $58.90M | $-47.20 | $2.29 |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 5, 2024 | Before market open | – | – | – |
Press releases
Announcements Mesa Laboratories filed with the SEC
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Mesa Labs Announces First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results
Results of operations · EX-99.1 to Form 8-K
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Mesa Labs Announces Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results
Results of operations · EX-99.1 to Form 8-K
MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mesa Labs Announces Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Laboratories Appoints Mark Capone to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Mesa Labs Announces Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Complementary Sterilization Indicators and Healthcare Channels to Mesa ’ s SDC Platform
Regulation FD disclosure · EX-99.1 to Form 8-K
Mesa Labs Announces First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces Unaudited Fourth Quarter and Full Fiscal Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure
Regulation FD disclosure · EX-99.1 to Form 8-K
Mesa Labs Announces Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Laboratories, Inc. Appoints Shiraz Ladiwala as Lead Independent Director
Regulation FD disclosure · EX-99.1 to Form 8-K
Mesa Labs Announces Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results
Results of operations · EX-99.1 to Form 8-K
For the nine months ended September 30, 2021
Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED DECEMBER 31, 2021
Other events · EX-99.2 to Form 8-K
Mesa Labs Announces Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Announces New Segment Reporting
Other events · EX-99.1 to Form 8-K
Mesa Labs Announces Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Mesa Labs Closes Acquisition of Agena Bioscience
Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K